{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:40:49Z","timestamp":1790253649292,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"French National Agency for Research on AIDS and Viral Hepatitis"},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1093\/jac\/dkz043","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T13:50:33Z","timestamp":1550238633000},"page":"1679-1692","source":"Crossref","is-referenced-by-count":11,"title":["HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen"],"prefix":"10.1093","volume":"74","author":[{"given":"Marine","family":"Perrier","sequence":"first","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Castain","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de Virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Regad","sequence":"additional","affiliation":[{"name":"Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris-Diderot, CNRS, INSERM, Biologie Fonctionnelle et Adaptative UMR 8251, Computational Modeling of Protein Ligand Interactions U1133, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Todesco","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de Virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Landman","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service de Maladies Infectieuses et Tropicales, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Visseaux","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service de Maladies Infectieuses et Tropicales, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"INSERM U955 Eq18, CNR h\u00e9patites virales B, C et delta, Laboratoire de Virologie, H\u00f4pital Henri Mondor, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Joly","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service de Maladies Infectieuses et Tropicales, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de Virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de Virologie, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"2019051708101818800_dkz043-B1","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1021\/bi00029a002","article-title":"Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure","volume":"34","author":"Gulnik","year":"1995","journal-title":"Biochemistry"},{"key":"2019051708101818800_dkz043-B2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/JVI.71.2.1089-1096.1997","article-title":"Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors","volume":"71","author":"Croteau","year":"1997","journal-title":"J Virol"},{"key":"2019051708101818800_dkz043-B3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1046\/j.1432-1327.1999.00514.x","article-title":"Structural and kinetic analysis of drug resistant mutants of HIV-1 protease","volume":"263","author":"Mahalingam","year":"1999","journal-title":"Eur J Biochem"},{"key":"2019051708101818800_dkz043-B4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1086\/605329","article-title":"Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V","volume":"200","author":"Nijhuis","year":"2009","journal-title":"J Infect Dis"},{"key":"2019051708101818800_dkz043-B5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet"},{"key":"2019051708101818800_dkz043-B6","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.aids.0000131332.30548.92","article-title":"SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir\/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients","volume":"18","author":"Gathe","year":"2004","journal-title":"AIDS"},{"key":"2019051708101818800_dkz043-B7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0b013e318198a815","article-title":"Gemini: a noninferiority study of saquinavir\/ritonavir versus lopinavir\/ritonavir as initial HIV-1 therapy in adults","volume":"50","author":"Walmsley","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019051708101818800_dkz043-B8","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/QAD.0b013e32832d9031","article-title":"Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial","volume":"23","author":"Souli\u00e9","year":"2009","journal-title":"AIDS"},{"key":"2019051708101818800_dkz043-B9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181c990bf","article-title":"Once-daily atazanavir\/ritonavir compared with twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study","volume":"53","author":"Molina","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019051708101818800_dkz043-B10","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1128\/JVI.76.15.7398-7406.2002","article-title":"Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro","volume":"76","author":"Maguire","year":"2002","journal-title":"J Virol"},{"key":"2019051708101818800_dkz043-B11","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1128\/JVI.71.9.6662-6670.1997","article-title":"Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites","volume":"71","author":"Zhang","year":"1997","journal-title":"J Virol"},{"key":"2019051708101818800_dkz043-B12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/00002030-200205030-00007","article-title":"Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity","volume":"16","author":"Prado","year":"2002","journal-title":"AIDS"},{"key":"2019051708101818800_dkz043-B13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/08892220050116970","article-title":"Polymorphism of HIV type 1 Gag p7\/p1 and p1\/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors","volume":"16","author":"Bally","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019051708101818800_dkz043-B14","doi-asserted-by":"crossref","first-page":"e24798.","DOI":"10.1371\/journal.pone.0024798","article-title":"Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir\/ritonavir single drug regimen","volume":"6","author":"Ghosn","year":"2011","journal-title":"PLoS One"},{"key":"2019051708101818800_dkz043-B15","doi-asserted-by":"crossref","first-page":"e36.","DOI":"10.1371\/journal.pmed.0040036","article-title":"A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism","volume":"4","author":"Nijhuis","year":"2007","journal-title":"PLoS Med"},{"key":"2019051708101818800_dkz043-B16","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1128\/AAC.02682-15","article-title":"Contribution of Gag and protease to HIV-1 phenotypic drug resistance in pediatric patients failing protease inhibitor-based therapy","volume":"60","author":"Giandhari","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019051708101818800_dkz043-B17","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25024","article-title":"Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya","volume":"20","author":"Coetzer","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2019051708101818800_dkz043-B18","doi-asserted-by":"crossref","first-page":"e0137834.","DOI":"10.1371\/journal.pone.0137834","article-title":"Evidence for reduced drug susceptibility without emergence of major protease mutations following protease inhibitor monotherapy failure in the SARA trial","volume":"10","author":"Sutherland","year":"2015","journal-title":"PLoS One"},{"key":"2019051708101818800_dkz043-B19","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1172\/JCI67399","article-title":"Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance","volume":"123","author":"Rabi","year":"2013","journal-title":"J Clin Invest"},{"key":"2019051708101818800_dkz043-B20","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1128\/JCM.01516-12","article-title":"Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes","volume":"50","author":"Gall","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2019051708101818800_dkz043-B21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"2019051708101818800_dkz043-B22","doi-asserted-by":"crossref","first-page":"W252","DOI":"10.1093\/nar\/gku340","article-title":"SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information","volume":"42","author":"Biasini","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2019051708101818800_dkz043-B23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0166-0934(01)00272-5","article-title":"HIV-1 subtyping using phylogenetic analysis of pol gene sequences","volume":"94","author":"Pasquier","year":"2001","journal-title":"J Virol Methods"},{"key":"2019051708101818800_dkz043-B24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-2836(02)00442-4","article-title":"Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations","volume":"320","author":"Guerois","year":"2002","journal-title":"J Mol Biol"},{"key":"2019051708101818800_dkz043-B25","doi-asserted-by":"crossref","first-page":"e0127816.","DOI":"10.1371\/journal.pone.0127816","article-title":"HIV-1 coreceptor usage assessment by ultra-deep pyrosequencing and response to maraviroc","volume":"10","author":"Rodriguez","year":"2015","journal-title":"PLoS One"},{"key":"2019051708101818800_dkz043-B26","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.1073\/pnas.1400027111","article-title":"Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir","volume":"111","author":"Hayashi","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019051708101818800_dkz043-B27","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1128\/JVI.05121-11","article-title":"Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1","volume":"85","author":"Koh","year":"2011","journal-title":"J Virol"},{"key":"2019051708101818800_dkz043-B28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0042-6822(02)00080-6","article-title":"Mutagenesis of the dimer interface residues of tethered and untethered HIV-1 protease result in differential activity and suggest multiple mechanisms of compensation","volume":"307","author":"Choudhury","year":"2003","journal-title":"Virology"},{"key":"2019051708101818800_dkz043-B29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/088922203766774586","article-title":"Natural polymorphisms of protease in protease inhibitor-naive HIV-1 infected patients in Korea: a novel L63M in subtype B","volume":"19","author":"Sung","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019051708101818800_dkz043-B30","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1128\/JVI.02212-05","article-title":"Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1\/p6 Gag cleavage site in drug resistance and replication fitness","volume":"80","author":"Brann","year":"2006","journal-title":"J Virol"},{"key":"2019051708101818800_dkz043-B31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s15010-008-8065-4","article-title":"Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients","volume":"37","author":"Santoro","year":"2009","journal-title":"Infection"},{"key":"2019051708101818800_dkz043-B32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.15.2.247-277.2002","article-title":"Genotypic testing for human immunodeficiency virus type 1 drug resistance","volume":"15","author":"Shafer","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"2019051708101818800_dkz043-B33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/bi027019u","article-title":"A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance","volume":"42","author":"Muzammil","year":"2003","journal-title":"Biochemistry"},{"key":"2019051708101818800_dkz043-B34","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1006\/jmbi.2000.4018","article-title":"How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease","volume":"301","author":"Prabu-Jeyabalan","year":"2000","journal-title":"J Mol Biol"},{"key":"2019051708101818800_dkz043-B35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jmb.2007.03.049","article-title":"Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development","volume":"369","author":"Sanches","year":"2007","journal-title":"J Mol Biol"},{"key":"2019051708101818800_dkz043-B36","doi-asserted-by":"crossref","first-page":"11559.","DOI":"10.1038\/s41598-017-11893-8","article-title":"Evolution of gag and gp41 in patients receiving ritonavir-boosted protease inhibitors","volume":"7","author":"Manasa","year":"2017","journal-title":"Sci Rep"},{"key":"2019051708101818800_dkz043-B37","volume-title":"Abstracts of the Fifteenth European Meeting on HIV & Hepatitis, Rome, Italy","author":"Blanch-Lombarte","year":"2017"},{"key":"2019051708101818800_dkz043-B38","volume-title":"Abstracts of the Twenty-fourth International HIV Drug Resistance Workshop, Seattle, WA, USA","author":"Lai","year":"2015"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/6\/1679\/28666627\/dkz043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T22:22:09Z","timestamp":1606515729000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/6\/1679\/5320332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,14]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz043","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,2,14]]}}}